Scarica l'app Stockscreener
3.16
3.36%
-0.11
Dopo l'orario di chiusura:
3.25
0.09
+2.85%
Precedente Chiudi:
$3.27
Aprire:
$3.24
Volume 24 ore:
70,958
Relative Volume:
0.31
Capitalizzazione di mercato:
$18.73M
Reddito:
$14.58M
Utile/perdita netta:
$-12.57M
Rapporto P/E:
-0.5563
EPS:
-5.68
Flusso di cassa netto:
$-13.07M
1 W Prestazione:
-15.05%
1M Prestazione:
-25.65%
6M Prestazione:
+7.12%
1 anno Prestazione:
-29.93%
Intervallo 1D:
$3.07
$3.35
Intervallo di 1 settimana:
$3.07
$3.81
Portata 52W:
$1.91
$6.28
Vivos Therapeutics Inc Stock (VVOS) Company Profile
Nome
Vivos Therapeutics Inc
Settore
Industria
Telefono
(866)908-4867
Indirizzo
7921 SOUTHPARK PLAZA,, LITTLETON
Confronta VVOS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VVOS
Vivos Therapeutics Inc
|
3.16 | 18.73M | 14.58M | -12.57M | -13.07M | -5.68 |
|
ABT
Abbott Laboratories
|
129.87 | 225.41B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.40 | 140.36B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
363.66 | 138.70B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.33 | 118.30B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
67.94 | 39.77B | 5.72B | 4.17B | 259.90M | 6.97 |
Vivos Therapeutics Inc Borsa (VVOS) Ultime notizie
Vivos Drives Innovation in Chronic Pain Care with Non-Invasive Treatment for Sleep Apnea - PR Web
Anti-Snoring Devices Markets: Oral Appliances, Nasal - GlobeNewswire
Anti-Snoring Devices Markets: Oral Appliances, Nasal Devices, Position Control DevicesGlobal Forecast to 2029 with ResMed, SomnoMed, ProSomnus, and Vivos Therapeutics, and DynaFlex Dominating - Yahoo Finance UK
Vivos Therapeutics Announces the Opening of the First Pneusomnia Integrated Medical-Dental Sleep Center - Marketscreener.com
Vivos Explores ‘Outright Acquisitions of Sleep Centers’ - Sleep Review
Vivos Therapeutics sees strong adoption of OSA treatment, expands strategic alliance - Proactive Investors UK
Vivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and Acquisitions Nationwide - The Manila Times
Vivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and - EIN News
This Sleep Apnea Treatment is Outperforming CPAP 2-to-1Can Vivos Transform Sleep Medicine? - StockTitan
Reviewing Vivos Therapeutics (NASDAQ:VVOS) & Biostage (OTCMKTS:BSTG) - Defense World
Vivos Therapeutics Inc to Host Earnings Call - ACCESS Newswire
Vivos Therapeutics to participate in Fireside Chat with Water Tower Research - Proactive Investors UK
Vivos Therapeutics to Participate in Fireside Chat with Water Tower Research on February 18, 2025 at 12:00 pm - EIN News
Revolutionary Sleep Apnea Treatment: Vivos CEO Reveals Market Strategy and Medical Partnerships - StockTitan
Investors Give Vivos Therapeutics, Inc. (NASDAQ:VVOS) Shares A 30% Hiding - Simply Wall St
Vivos Therapeutics Enters Into At The Market Offering Agreement with H.C. Wainwright & Co., LLC**Littleton, Colo. – Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced on February 14, 2025, that the company has entered into an At The Market Offering - Defense World
Vivos Therapeutics Enters Market Offering Agreement with Wainwright - TipRanks
Vivos Therapeutics announces up to $50M mixed shelf offering - MSN
Vivos Therapeutics Inc Files For Mixed Shelf Of Up To $50 MillionSEC Filing -February 11, 2025 at 05:44 pm EST - Marketscreener.com
Cancer Breakthrough: Vivos RadioGel Eliminates 80% of Tumor Mass in Groundbreaking Trial - StockTitan
Trapped in CPAP Dependency? Vivos Liberates OSA Patients with Non-Invasive Solution - PR Web
Vivos Therapeutics announces sale of up to 854,332 shares by selling stockholders - MSN
Vivos Therapeutics (VVOS) Stock Price, News & Analysis - MarketBeat
VVOS Stock Price and Chart — NASDAQ:VVOS — TradingView«Кавказ Пост» - «Кавказ Пост» - новости Северного Кавказа и Закавказья
Best Momentum Stocks to Buy for January 8th - MSN
Recognizing Sleep as the Sixth Vital Sign: How Vivos Is Redefining Health Care - PR Web
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Up 28.9% in December - Defense World
After Leaping 35% Vivos Therapeutics, Inc. (NASDAQ:VVOS) Shares Are Not Flying Under The Radar - Simply Wall St
Vivos Therapeutics announces $3.5 million stock offering - Investing.com
Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
Vivos Therapeutics Secures $3.5M Financing Through Strategic Share Offering and Warrants - StockTitan
Vivos Therapeutics announces funding boost - Proactive Investors USA
Vivos Inc. Announces Launch of Groundbreaking RadioGel® Precision Radionuclide Therapy™ Human Clinical Trial - GlobeNewswire
Vivos Therapeutics (NASDAQ:VVOS) Stock Price Up 6.9% – What’s Next? - Defense World
All You Need to Know About Vivos Therapeutics (VVOS) Rating Upgrade to Buy - Yahoo Finance
FDA-Cleared Therapy for Pediatric Sleep Apnea From Vivos Offers Parents and Providers New Hope - PR Web
Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga
Water Tower Research Publishes Initiation of Coverage Report on Vivos Therapeutics, Inc., "New Strategic Model & Key Regulatory Milestones Provide Revenue Tailwind" - Big News Network
Vivos, Cellev8 Launch Strategic Sleep Apnea Venture: FDA-Cleared Devices Meet Breakthrough Nutraceuticals - StockTitan
Groundbreaking Collaboration: Vivos Therapeutics and Cellev8 Nutrition Join Forces to Address Sleep Apnea and Oxidative Stress - ACCESS Newswire
Vivos and SleepImage © Revolutionize Sleep Apnea Diagnostics with Affordable Home Sleep Testing Solutions - PR Web
Vivos Therapeutics shareholders elect directors, approve equity plan By Investing.com - Investing.com South Africa
Vivos Therapeutics shareholders elect directors, approve equity plan - Investing.com India
Sleep Apnea: Vivos' FDA-Cleared Technology Offers Revolutionary, Non-Invasive Hope for America's Stealth Epidemic - PR Web
Medicare to reimburse for Vivos CARE sleep apnea devices - MSN
Ascendiant Capital Markets Reiterates Buy Rating for Vivos Therapeutics (NASDAQ:VVOS) - Defense World
Vivos Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Vivos Therapeutics Inc Azioni (VVOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.50%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):